Skip to content
DraconiticResearch
Search Sources API
201,818 studies31 sourcesUpdated 40 min ago
Peer-reviewedCC BYJournal for ImmunoTherapy of Cancer

1175 Combining PSMAxCD28 costimulatory T cell engager (TCE) JNJ-87189401 with pasritamig (KLK2xCD3): first-in-human phase 1 results of a dual-antigen targeted TCE regimen in prostate cancer

  • Wei Chen1
  • Shahneen Sandhu2
  • Shigehisa Kitano3
  • Song Zhao4
  • Christophe Massard5
  • Aaron R Hansen6
  • Armelle Vinceneux7
  • Fei Shen8
  • Daksh Thaper9
  • Josh Lauring9
  • Charles G Drake8
  • Mark N Stein10
15 more authors
  • Nicholas A Zorko11
  • Laura S Graham12
  • Mehmet A Bilen13
  • Drew W Rasco14
  • W Kevin Kelly15
  • Diego Teyssonneau16
  • Sumit K Subudhi17
  • Alexandra O Sokolova18
  • Earle F Burgess19
  • Jeffrey Russell20
  • Bruno S Fang21
  • Leanne Cartee22
  • Debopriya Ghosh23
  • Jessica E Hawley8
  • Trishala Agrawal8
23 affiliations
  1. 1Neurodawn Pharmaceutical Company, Nanjing, Jiangsu, China
  2. 2Peter MacCallum Cancer Center, Melbourne, Australia
  3. 3Advanced Medical Development Center, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan
  4. 4Aff3 grid.412633.1Department of Thoracic Surgerythe First Affiliated Hospital of Zhengzhou University Zhengzhou China
  5. 51Gustave Roussy Cancer Campus, Villejuif, France
  6. 6Division of Medical Oncology and Haematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
  7. 7Department of Medical Oncology, Centre Léon Bérard, Lyon, France
  8. 8Johnson & Johnson, Spring House, PA, USA
  9. 9Johnson & Johnson Innovative Medicine, Spring House, PA, USA
  10. 10Columbia University Medical Center, New York, NY, USA
  11. 11University of Minnesota, Minneapolis, MN, USA
  12. 12University of Colorado, Aurora, CO, USA
  13. 13Winship Cancer Institute of Emory University, Atlanta, GA, USA
  14. 14START - San Antonio, San Antonio, TX, USA
  15. 15Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA
  16. 16Institut Bergonié, Bordeaux, France
  17. 17The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
  18. 18Oregon Health & Science University, Portland, OR, USA
  19. 19Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Charlotte, NC, USA
  20. 20Tennessee Oncology, Nashville, TN, USA
  21. 21START - New Jersey, East Brunswick, NJ, USA
  22. 22Johnson & Johnson, Horsham, PA, USA
  23. 23Johnson & Johnson, Raritan, NJ, USA
Open at sourcePDFDOICite

Related

  1. Investigating the role of costimulatory domains in enhancing CAR-T cell persistence in TNBC
    Hany E. Marei, Giacomo Pozzoli, Carlo Cenciarelli
    Cancer Gene TherapyPeer-reviewedCC BY 4.0Full text1 citedOncologyPMC
  2. ENGINEERING MANNAN-SPECIFIC CHIMERIC ANTIGEN RECEPTOR (M-CAR) T CELLS WITH DISTINCT COSTIMULATORY DOMAINS TO IMPROVE ANTIFUNGAL ACTIVITY AGAINST
    Julia Garcia GUIMARÃES, Gabriela Yamazaki DE CAMPOS, Michele Procópio MACHADO +3
    Hematology, Transfusion and Cell TherapyPeer-reviewedCC BYFull textOncologyDOAJ
  3. Integrated risk prediction for opioid overdose: combining genetic and socioeconomic factors
    Mupeng Lei, Yan Yuan
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textEpidemiology & public healthCrossref
  4. COMBINING CHEST X-RAY AND CLINICAL COVARIATES FOR OSTEOPOROSIS SCREENING: A MULTIMODAL DEEP LEARNING APPROACH
    v. kobayashi, G. Baluyut, J. Punsalan
    medRxivPreprintAll rights reservedFull textEpidemiology & public healthmedRxiv
  5. MuscleSCS: a standardized programming framework combining neural neuromodulation and spinally mediated paraspinal muscle modulation
    Matthias Hubert Morgalla
    Frontiers in pain research (Lausanne, Switzerland)Peer-reviewedCC BYFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{chen20261175,
  title = {{1175 Combining PSMAxCD28 costimulatory T cell engager (TCE) JNJ-87189401 with pasritamig (KLK2xCD3): first-in-human phase 1 results of a dual-antigen targeted TCE regimen in prostate cancer}},
  author = {Wei Chen and Shahneen Sandhu and Shigehisa Kitano and Song Zhao and Christophe Massard and Aaron R Hansen and Armelle Vinceneux and Fei Shen and Daksh Thaper and Josh Lauring and Charles G Drake and Mark N Stein and Nicholas A Zorko and Laura S Graham and Mehmet A Bilen and Drew W Rasco and W Kevin Kelly and Diego Teyssonneau and Sumit K Subudhi and Alexandra O Sokolova and Earle F Burgess and Jeffrey Russell and Bruno S Fang and Leanne Cartee and Debopriya Ghosh and Jessica E Hawley and Trishala Agrawal},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  month = nov,
  doi = {10.1136/jitc-2026-sitc2026.1175},
  url = {https://doi.org/10.1136/jitc-2026-sitc2026.1175},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - 1175 Combining PSMAxCD28 costimulatory T cell engager (TCE) JNJ-87189401 with pasritamig (KLK2xCD3): first-in-human phase 1 results of a dual-antigen targeted TCE regimen in prostate cancer
AU  - Wei Chen
AU  - Shahneen Sandhu
AU  - Shigehisa Kitano
AU  - Song Zhao
AU  - Christophe Massard
AU  - Aaron R Hansen
AU  - Armelle Vinceneux
AU  - Fei Shen
AU  - Daksh Thaper
AU  - Josh Lauring
AU  - Charles G Drake
AU  - Mark N Stein
AU  - Nicholas A Zorko
AU  - Laura S Graham
AU  - Mehmet A Bilen
AU  - Drew W Rasco
AU  - W Kevin Kelly
AU  - Diego Teyssonneau
AU  - Sumit K Subudhi
AU  - Alexandra O Sokolova
AU  - Earle F Burgess
AU  - Jeffrey Russell
AU  - Bruno S Fang
AU  - Leanne Cartee
AU  - Debopriya Ghosh
AU  - Jessica E Hawley
AU  - Trishala Agrawal
PY  - 2026
DA  - 2026/11/08
JO  - Journal for ImmunoTherapy of Cancer
DO  - 10.1136/jitc-2026-sitc2026.1175
UR  - https://doi.org/10.1136/jitc-2026-sitc2026.1175
SN  - 2051-1426
ER  -